|
|
Multidisciplinary Team Essentials on CMV Prevention, Surveillance, and Treatment Optimization in the Transplant Setting
The role of the multidisciplinary transplant team has expanded considerably over the past decade to keep pace with advances in the field and to address long-term care of transplant recipients. Despite these advances, breakthrough cytomegalovirus (CMV) infections and development of refractory and resistant CMV infections cause significant complications post-transplant. To lessen patient burden and improve survival outcomes, optimal introduction of anti-CMV drugs, both prophylactically and thera... |
|
|
Pediatric RSV Prophylaxis: An Evolving Landscape for Prevention " A Wheel of Knowledge Challenge!
Respiratory syncytial virus (RSV) is the most common cause of bronchiolitis and pneumonia in children younger than 1 year of age in the United States. Although certain infants and young children are at higher risk for severe illness due to premature birth or comorbid conditions, the majority of pediatric RSV hospitalizations occur in healthy infants. Emerging passive immunization options, which include nirsevimab and a maternal RSV vaccine, provide important new tools that offer RSV protection... |
|
|
Bridging the Health Gaps in Hereditary Angioedema: Demystifying Disparities, Enhancing Quality of Life, and Implementing Effective Prophylactic Solutions
Hereditary angioedema (HAE) is a rare, life-threatening disorder characterized by recurrent, unpredictable episodes of bradykinin-induced swelling. In this presentation, Dr. Marc Reidl, Clinical Director of the US Hereditary Angioedema Association (HAEA) Angioedema Center, reviews multiple underrecognized factors that contribute to health disparities among patients with HAE, including delays in diagnosis and multifaceted differences among racial and ethnic groups, socioeconomic status levels, ... |
|
|
Pediatric RSV Prevention " Unlocking New Insights
Respiratory syncytial virus (RSV) is a leading cause of bronchiolitis and pneumonia in infants and young children, particularly those under 1 year of age in the United States. While infants born prematurely or with underlying health conditions are at a higher risk for severe RSV illness, the majority of pediatric RSV hospitalizations occur in otherwise healthy infants. Recent advancements in passive immunization, including long-acting monoclonal antibodies and maternal RSV vaccines, introduce ... |
|